Janssen Biotech gets an option to Effimune's FR104; option exercised; rights returned to OSE
Effimune SAS (therapeutics that regulate the immune system) granted Johnson & Johnson’s Janssen Biotech Inc. an exclusive option to develop and commercialize FR104, a preclinical monoclonal antibody fragment for immune-mediated disorders.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com